# Agios Pharmaceuticals Inc. (AGIO)

Source: https://www.quantisnow.com/company/AGIO
Generated: 2026-11-11T22:01:42.991Z

- Ticker: AGIO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2013
- SEC CIK: 0001439222
- Website: agios.com

## About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

## Latest AGIO news and filings

- 2026-11-05 14:38 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Agios Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-agios-pharmaceuticals-inc-6775251)
- 2026-11-05 11:33 UTC [SEC Form 8-K] [Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/agios-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6774235)
- 2026-11-05 11:30 UTC [Earnings] [Agios Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/agios-reports-third-quarter-2026-financial-results-and-provides-business-6774186)
- 2026-11-04 14:01 UTC [Conference Announcement] [Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026](https://www.quantisnow.com/insight/agios-to-highlight-strength-and-differentiation-of-rare-hematology-portfolio-6771689)
- 2026-10-30 11:00 UTC [Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA](https://www.quantisnow.com/insight/agios-announces-new-pdufa-goal-date-of-february-1-2027-6764436)
- 2026-10-29 12:37 UTC [Analyst Coverage Resumed] [H.C. Wainwright resumed coverage on Agios Pharma with a new price target](https://www.quantisnow.com/insight/hc-wainwright-resumed-coverage-on-agios-pharma-with-a-new-6762826)
- 2026-10-28 20:02 UTC [SEC Form 4] [Chief Medical Officer Gheuens Sarah sold $296,470 worth of shares (7,866 units at $37.69) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-gheuens-sarah-sold-296470-worth-of-shares-6761213)
- 2026-10-23 20:05 UTC [SEC Form 4] [Chief Medical Officer Gheuens Sarah sold $74,642 worth of shares (1,989 units at $37.53) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-gheuens-sarah-sold-74642-worth-of-shares-6756279)
- 2026-10-20 12:59 UTC [A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday](https://www.quantisnow.com/insight/a-phase-3-win-and-a-130-takeover-premium-lit-6751698)
- 2026-10-08 11:00 UTC [Earnings Date] [Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET](https://www.quantisnow.com/insight/agios-to-host-third-quarter-2026-financial-results-conference-call-6740985)
- 2026-09-28 12:08 UTC [FDA Approval for PYRUKYND issued to AGIOS PHARMS INC](https://www.quantisnow.com/insight/fda-approval-for-pyrukynd-issued-to-agios-pharms-inc-6727202)
- 2026-09-28 12:08 UTC [FDA Approval for AQVESME issued to AGIOS PHARMS INC](https://www.quantisnow.com/insight/fda-approval-for-aqvesme-issued-to-agios-pharms-inc-6727201)
- 2026-08-06 20:13 UTC [SEC Form 4] [Chief Medical Officer Gheuens Sarah sold $914,400 worth of shares (30,000 units at $30.48) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 54,645 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-gheuens-sarah-sold-914400-worth-of-shares-6669229)
- 2026-08-03 12:30 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-agios-pharmaceuticals-inc-6658891)
- 2026-07-30 13:56 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Agios Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-agios-pharmaceuticals-inc-6655425)
- 2026-07-30 10:32 UTC [SEC Form 8-K] [Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/agios-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6654727)
- 2026-07-30 10:30 UTC [Earnings Date] [Agios Reports Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/agios-reports-second-quarter-2026-financial-results-and-provides-business-6654699)
- 2026-07-21 11:00 UTC [Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease](https://www.quantisnow.com/insight/agios-provides-update-on-phase-2-trial-of-tebapivat-in-6643112)
- 2026-07-10 20:18 UTC [SEC Form 4] [Director Backstrom Jay T. was granted 1,447 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-backstrom-jay-t-was-granted-1447-shares-sec-form-6634182)
- 2026-07-07 11:00 UTC [U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease](https://www.quantisnow.com/insight/us-fda-grants-priority-review-to-agios-snda-for-mitapivat-6629365)
- 2026-07-02 20:04 UTC [SEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-agios-pharmaceuticals-inc-6625079)
- 2026-07-02 20:03 UTC [SEC Form 4] [Chief Medical Officer Gheuens Sarah sold $150,503 worth of shares (4,007 units at $37.56) as part of a pre-agreed trading plan and converted options into 8,375 shares, increasing direct ownership by 5% to 84,645 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/chief-medical-officer-gheuens-sarah-sold-150503-worth-of-shares-6625047)
- 2026-06-29 11:00 UTC [Earnings Date] [Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET](https://www.quantisnow.com/insight/agios-to-host-second-quarter-2026-financial-results-conference-call-6618166)
- 2026-06-23 21:25 UTC [SEC Form 4] [Director Ballal Rahul D. converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ballal-rahul-d-converted-options-into-2816-shares-increasing-6613076)
- 2026-06-23 21:24 UTC [SEC Form 4] [Director Capello Jeffrey D converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)](https://www.quantisnow.com/insight/director-capello-jeffrey-d-converted-options-into-2816-shares-increasing-6613072)
- 2026-06-23 21:23 UTC [SEC Form 4] [Director Foster-Cheek Kaye I converted options into 2,816 shares, increasing direct ownership by 38% to 10,284 units (SEC Form 4)](https://www.quantisnow.com/insight/director-foster-cheek-kaye-i-converted-options-into-2816-shares-increasing-6613070)
- 2026-06-23 21:22 UTC [SEC Form 4] [Director Fouse Jacqualyn A converted options into 2,816 shares, increasing direct ownership by 2% to 154,156 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fouse-jacqualyn-a-converted-options-into-2816-shares-increasing-6613067)
- 2026-06-23 21:21 UTC [SEC Form 4] [Director Ho Maykin converted options into 2,816 shares, increasing direct ownership by 17% to 19,848 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ho-maykin-converted-options-into-2816-shares-increasing-direct-6613063)
- 2026-06-23 21:21 UTC [SEC Form 4] [Director Owen Adams Catherine converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)](https://www.quantisnow.com/insight/director-owen-adams-catherine-converted-options-into-2816-shares-increasing-6613059)
- 2026-06-23 21:20 UTC [SEC Form 4] [Director Scadden David converted options into 2,816 shares, increasing direct ownership by 16% to 20,419 units (SEC Form 4)](https://www.quantisnow.com/insight/director-scadden-david-converted-options-into-2816-shares-increasing-direct-6613055)
- 2026-06-23 21:19 UTC [SEC Form 4] [Director Smith Cynthia converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)](https://www.quantisnow.com/insight/director-smith-cynthia-converted-options-into-2816-shares-increasing-direct-6613045)
- 2026-06-23 21:18 UTC [SEC Form 4] [SEC Form 4 filed by Chief Strategy and Operations Viswanadhan Krishnan](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-strategy-and-operations-viswanadhan-6613040)
- 2026-06-23 21:17 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Goff Brian](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-goff-brian-6613036)
- 2026-06-23 21:16 UTC [SEC Form 4] [SEC Form 4 filed by Chief Legal Officer Burns James William](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-legal-officer-burns-james-6613028)
- 2026-06-23 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Gheuens Sarah](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-gheuens-sarah-6613022)
- 2026-06-23 21:14 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Jones Cecilia](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-jones-cecilia-6613011)
- 2026-06-23 21:13 UTC [SEC Form 4] [SEC Form 4 filed by Chief Commercial Officer Milanova Tsveta](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-milanova-tsveta-6613010)
- 2026-06-23 21:12 UTC [SEC Form 4] [SEC Form 4 filed by Director Backstrom Jay T.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-backstrom-jay-t-6613007)
- 2026-06-18 20:15 UTC [SEC Form S-8] [SEC Form S-8 filed by Agios Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-agios-pharmaceuticals-inc-6608796)
- 2026-06-18 20:13 UTC [SEC Form 8-K] [SEC Form 8-K filed by Agios Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-agios-pharmaceuticals-inc-6608728)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AGIO
- Earnings history: https://www.quantisnow.com/earnings/AGIO
- Dividend history: https://www.quantisnow.com/dividends/AGIO
- Insider transactions: https://www.quantisnow.com/insiders/AGIO
- Options chain: https://www.quantisnow.com/options/AGIO
- SEC 8-K filings only: https://www.quantisnow.com/company/AGIO/8-k
- RSS and alerts for AGIO: https://www.quantisnow.com/docs/rss-feeds.md